Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status

Palanivel Ganesan,1,2 Palanisamy Arulselvan,3 Dong-Kug Choi1,2 1Nanotechnology Research Center and Department of Applied Life Science, 2Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea; 3Laboratory of Vaccines and Immunotherapeutics...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ganesan P, Arulselvan P, Choi DK
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Type 2 diabetes
Nanodelivery system
Phyto bioactive compounds
Oraldelivery
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/f10b0a476c0e4ee3b4e935afc2961deb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f10b0a476c0e4ee3b4e935afc2961deb
record_format dspace
spelling oai:doaj.org-article:f10b0a476c0e4ee3b4e935afc2961deb2021-12-02T02:42:33ZPhytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status1178-2013https://doaj.org/article/f10b0a476c0e4ee3b4e935afc2961deb2017-02-01T00:00:00Zhttps://www.dovepress.com/phytobioactive-compound-based-nanodelivery-systems-for-the-treatment-o-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Palanivel Ganesan,1,2 Palanisamy Arulselvan,3 Dong-Kug Choi1,2 1Nanotechnology Research Center and Department of Applied Life Science, 2Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea; 3Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia Abstract: Type 2 diabetes mellitus (T2DM) is a major chronic disease that is prevalent worldwide, and it is characterized by an increase in blood glucose, disturbances in the metabolism, and alteration in insulin secretion. Nowadays, food-based therapy has become an important treatment mode for type 2 diabetes, and phytobioactive compounds have gained an increasing amount of attention to this end because they have an effect on multiple biological functions, including the sustained secretion of insulin and regeneration of pancreatic islets cells. However, the poor solubility and lower permeability of these phyto products results in a loss of bioactivity during processing and oral delivery, leading to a significant reduction in the bioavailability of phytobioactive compounds to treat T2DM. Recently, nanotechnological systems have been developed for use as various types of carrier systems to improve the delivery of bioactive compounds and thus obtain a greater bioavailability. Furthermore, carrier systems in most nanodelivery systems are highly biocompatible, with nonimmunologic behavior, a high degree of biodegradability, and greater mucoadhesive strength. Therefore, this review focuses on the various types of nanodelivery systems that can be used for phytobioactive compounds in treating T2DM with greater antidiabetic effects. There is also additional focus on improving the effects of various phytobioactive compounds through nanotechnological delivery to ensure a highly efficient treatment of type 2 diabetes. Keywords: type 2 diabetes, nanodelivery system, phytobioactive compounds, oral deliveryGanesan PArulselvan PChoi DKDove Medical PressarticleType 2 diabetesNanodelivery systemPhyto bioactive compoundsOraldeliveryMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 1097-1111 (2017)
institution DOAJ
collection DOAJ
language EN
topic Type 2 diabetes
Nanodelivery system
Phyto bioactive compounds
Oraldelivery
Medicine (General)
R5-920
spellingShingle Type 2 diabetes
Nanodelivery system
Phyto bioactive compounds
Oraldelivery
Medicine (General)
R5-920
Ganesan P
Arulselvan P
Choi DK
Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
description Palanivel Ganesan,1,2 Palanisamy Arulselvan,3 Dong-Kug Choi1,2 1Nanotechnology Research Center and Department of Applied Life Science, 2Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea; 3Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia Abstract: Type 2 diabetes mellitus (T2DM) is a major chronic disease that is prevalent worldwide, and it is characterized by an increase in blood glucose, disturbances in the metabolism, and alteration in insulin secretion. Nowadays, food-based therapy has become an important treatment mode for type 2 diabetes, and phytobioactive compounds have gained an increasing amount of attention to this end because they have an effect on multiple biological functions, including the sustained secretion of insulin and regeneration of pancreatic islets cells. However, the poor solubility and lower permeability of these phyto products results in a loss of bioactivity during processing and oral delivery, leading to a significant reduction in the bioavailability of phytobioactive compounds to treat T2DM. Recently, nanotechnological systems have been developed for use as various types of carrier systems to improve the delivery of bioactive compounds and thus obtain a greater bioavailability. Furthermore, carrier systems in most nanodelivery systems are highly biocompatible, with nonimmunologic behavior, a high degree of biodegradability, and greater mucoadhesive strength. Therefore, this review focuses on the various types of nanodelivery systems that can be used for phytobioactive compounds in treating T2DM with greater antidiabetic effects. There is also additional focus on improving the effects of various phytobioactive compounds through nanotechnological delivery to ensure a highly efficient treatment of type 2 diabetes. Keywords: type 2 diabetes, nanodelivery system, phytobioactive compounds, oral delivery
format article
author Ganesan P
Arulselvan P
Choi DK
author_facet Ganesan P
Arulselvan P
Choi DK
author_sort Ganesan P
title Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
title_short Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
title_full Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
title_fullStr Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
title_full_unstemmed Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
title_sort phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/f10b0a476c0e4ee3b4e935afc2961deb
work_keys_str_mv AT ganesanp phytobioactivecompoundbasednanodeliverysystemsforthetreatmentoftype2diabetesmellitusndashcurrentstatus
AT arulselvanp phytobioactivecompoundbasednanodeliverysystemsforthetreatmentoftype2diabetesmellitusndashcurrentstatus
AT choidk phytobioactivecompoundbasednanodeliverysystemsforthetreatmentoftype2diabetesmellitusndashcurrentstatus
_version_ 1718402258489573376

Ejemplares similares